Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies. Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-a2a
In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a
β Scribed by de Riese, W. ;Allhoff, E. ;Stief, C. G. ;Lenis, G. ;Schlick, R. ;Liedke, S. ;Anton, P. ;Jonas, U.
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 602 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
β¦ Synopsis
Samples of 38 human renal cell carcinomas (RCC) were subjected to routine histopathological examination but also to in vitro sensitivity testing with mitomycin C, vinblastine and interferon Alpha-2a at various concentrations corresponding to serum titers recommended to be effective in vivo, employing a monolayer assay. Extending earlier in vitro studies, both tumor cell kill rates (TCKR) and proliferation rates (PR) were assessed. Following in vitro preparation the tumor cell cultures were simultaneously exposed to the anticancer drugs listed above. The proliferation rates were determined immunocytochemically using the monoclonal antibody Ki-67. Nine (23.7%) of the tumors investigated revealed temporary and limited response with respect to either TCKR or PR. Improvement of this percentage could only be obtained by increasing drug concentration to titers with toxicity intolerable for in vivo administration. The in vivo data presented correspond to clinical temporary and limited remissions in patients with metastatic RCC ranging up to 25 %.
π SIMILAR VOLUMES
Whereas cytokine therapy has proven efficacy in the treatment of metastatic renal cell carcinoma (RCC), many questions regarding the use of these drugs remain unanswered. In the present study we evaluated the antiproliferative effects of human recombinant alpha-interferon (IFN), gamma-interferon and
## Abstract This study was undertaken to elucidate the mechanism(s) of potentiation of cisplatin (CDDP) cytotoxicity by interferon Ξ±β2a (IFN Ξ±β2a) in human squamous carcinoma cell lines SCCβ25 and SCCβ4. IFN Ξ±β2a treatment significantly increased the cytotoxicity of CDDP in both cell lines in a dos
Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN